Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.38 |
| ▸ | BRAF | P15056 | 1/20 | 0.34 |
| ▸ | MGLL | Q99685 | 3/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.32 |
| ▸ | MMP2 | P08253 | 1/20 | 0.32 |
| ▸ | MMP3 | P08254 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.32 |
| ▸ | SETD7 | Q8WTS6 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14841645 | 0.91 | RAB9A (0.36) | GPR35MGLLRAB9AKCNH2MMP2 | |
| SCHEMBL4108959 | 0.85 | MGLL (0.45) | MGLLRAB9APOLBKMT2AMMP2 | |
| SCHEMBL14881197 | 0.85 | MGLL (0.37) | GPR35MGLLRAB9AKMT2AKCNH2 | |
| SCHEMBL509995 | 0.78 | MGLL (0.46) | MGLLMCHR1SMN1; SMN2 | |
| SCHEMBL508483 | 0.77 | L3MBTL1 (0.36) | POLBKMT2ASMN1; SMN2 | |
| SCHEMBL15262747 | 0.72 | PPARG (0.43) | SMN1; SMN2 | |
| SCHEMBL15262418 | 0.72 | MAPT (0.40) | KMT2ASMN1; SMN2 | |
| SCHEMBL15633184 | 0.71 | GPR35 (0.45) | GPR35BRAFKMT2AKCNH2 | |
| SCHEMBL509178 | 0.71 | MGLL (0.34) | MGLLRAB9A | |
| SCHEMBL27561768 | 0.71 | PPARA (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7230025-B2 | Pyrazole derivatives | PFIZER, INC. (US) | 2007-06-12 | — | — | US | disclosed |
| US-7230025-B2 | Pyrazole derivatives | PFIZER, INC. (US) | 2007-06-12 | — | — | US | disclosed |
| US-7230025-B2 | Pyrazole derivatives | PFIZER, INC. (US) | 2007-06-12 | — | — | US | disclosed |
| EP-1546132-A1 | PYRAZOLE DERIVATIVES AS REVERSE TRANSCRIPTASE INHIBITORS | Pfizer Limited (GB) | 2005-06-29 | — | — | EP | disclosed |
| US-20040110816-A1 | Pyrazole derivatives | PFIZER, INC. | 2004-06-10 | — | — | US | disclosed |
| WO-2004029042-A1 | PYRAZOLE DERIVATIVES AS REVERSE TRANSCRIPTASE INHIBITORS | PFIZER LIMITED (GB) | 2004-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110816-A1 | Pyrazole derivatives | REV1, POLR2E, SARS1 | GPR35 2685/4885BRAF 2201/4885MGLL 4492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.